EuroBiotech Report—Disley takes CEO post, Moroney to leave MorphoSys, Arix CEO and Realm

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with the stories of three CEOs, one who is arriving, one who is leaving and a third who left only to come back. Darrin Disley, once of Horizon Discovery, is the arrival. Disley has taken over as CEO of cell therapy startup Mogrify and invested in the company. The departing CEO is Simon Moroney, who plans to end his reign as leader of MorphoSys by June 2020. Our third CEO is Joe Anderson, who left the top job at Arix Bioscience last year to take up the chief investment officer role. Five months later, Arix has identified his replacement as CEO: Joe Anderson. Elsewhere, Realm Therapeutics outlined plans to drop its London stock listing. And more. — Nick Taylor
 
1. Darrin Disley takes CEO role at cell therapy startup

Cell Mogrify has named ex-Horizon Discovery CEO Darrin Disley as its leader. Disley joined Mogrify and participated in its seed round to advance technology for direct reprogramming between mature cell types.

 
2. MorphoSys CEO Moroney announces his retirement

MorphoSys co-founder Simon Moroney announced his plans to retire from the company. He will step down as CEO after his current contract expires in June 2020, or earlier if a successor is appointed before that time.

3. Arix reappoints CEO 5 months after starting hunt for replacement

Arix Bioscience’s five-month search for a CEO has ended with it reappointing the person who vacated the role at the start of the process. Joe Anderson stepped down as CEO in September to take up the chief investment officer position but now finds himself back in charge of the company.
 
4. Realm set to offload assets, leave London following failures

Realm Therapeutics is set to sell assets and drop its London stock listing. The actions are part of the biotech’s ongoing efforts to seek a way out of its R&D-triggered troubles. 
 
And more articles of note>>